Corporate Profile

CalciMedica is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica’s proprietary technology targets the inhibition of CRAC channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are currently no approved therapies.

Learn More

Stock Information

Minimum 15 minutes delayed. Source:

Featured Events

View all Events

Featured Reports

View all Reports

Press Releases

16 Oct 24

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

LA JOLLA, Calif. , Oct. 16, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica ") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic
03 Sep 24

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference

LA JOLLA, Calif. , Sept. 3, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica ") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic
12 Aug 24

CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Positive topline data announced from CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year First patient enrolled in KOURAGE, Phase 2 trial of Auxora™ in severe acute kidney injury (AKI), with data expected in 2025 LA
09 Jul 24

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)

Development of Auxora in AKI is supported by both clinical and pre-clinical evidence Topline data expected in 2025 LA JOLLA, Calif. , July 9, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica " or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing
View all Releases
Explore More
Our Technologies
Our Pipeline
Our Story
Our Team